SB-209670

• CAT Number: I008733
• CAS Number: 157659-79-5
• Molecular Formula: C29H28O9
• Molecular Weight: 520.534
• Purity: ≥95%
• Target: endothelin receptor antagonist
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: (1S,2R,3S)-1-(1,3-benzodioxol-5-yl)-3-[2-(carboxymethoxy)-4-methoxyphenyl]-5-propoxy-2,3-dihydro-1H-indene-2-carboxylic acid
• InChI: InChI=1S/C29H28O9/c1-3-10-35-18-6-7-19-21(12-18)27(20-8-5-17(34-2)13-23(20)36-14-25(30)31)28(29(32)33)26(19)16-4-9-22-24(11-16)38-15-37-22/h4-9,11-13,26-28H,3,10,14-15H2,1-2H3,(H,30,31)(H,32,33)/t26-,27+,28+/m0/s1
• InChIKey: UUAVCCWBNUITBB-UPRLRBBYSA-N
• SMILES: CCCOC1=CC2=C(C=C1)C(C(C2C3=C(C=C(C=C3)OC)OCC(=O)O)C(=O)O)C4=CC5=C(C=C4)OCO5

SB-209670 (Cat.No:I008733) is a endothelin receptor antagonist. SB 209670 inhibits the arrhythmogenic actions of endothelin-1 in the anesthetized dog. SB 209670 selectively antagonize vascular endothelial versus vascular smooth muscle ET(B)-receptor activity in the rat. 

Reference

1:Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ.J Pharmacol Exp Ther. 2000 Jan;292(1):449-59. PMID: 10604982 Free Article2:Differential haemodynamic effects of endothelin receptor antagonist, SB 209670, in conscious hypertensive and normotensive rats. Bunting MW, Widdop RE.Eur J Pharmacol. 1999 Sep 17;381(1):13-21. PMID: 10528129 3:Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone. Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK.Clin Pharmacol Ther. 1999 May;65(5):473-82. PMID: 10340912 4:PD 142893, SB 209670, and BQ 788 selectively antagonize vascular endothelial versus vascular smooth muscle ET(B)-receptor activity in the rat. Schroeder RL, Keiser JA, Cheng XM, Haleen SJ.J Cardiovasc Pharmacol. 1998 Dec;32(6):935-43. PMID: 9869499 5:SB 209670 inhibits the arrhythmogenic actions of endothelin-1 in the anesthetized dog. Douglas SA, Nichols AJ, Feuerstein GZ, Elliott JD, Ohlstein EH.J Cardiovasc Pharmacol. 1998;31 Suppl 1:S99-102. PMID: 9595411 6:Effect of the endothelin receptor antagonist, SB 209670 on cyclosporine-induced nephrotoxicity. Ishikawa A, Suzuki K, Fujita K.Transplant Proc. 1998 Feb;30(1):40-2. No abstract available. PMID: 9474951 7:Nonpeptide endothelin receptor antagonists. IX. Characterization of endothelin receptors in guinea pig bronchus with SB 209670 and other endothelin receptor antagonists. Hay DW, Luttmann MA.J Pharmacol Exp Ther. 1997 Feb;280(2):959-65. PMID: 9023312 Free Article8:Influence of aminoguanidine and the endothelin antagonist, SB 209670, on the regional haemodynamic effects of endotoxaemia in conscious rats. Gardiner SM, Kemp PA, March JE, Bennett T.Br J Pharmacol. 1996 Aug;118(7):1822-8. PMID: 8842449 Free PMC Article9:Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors. Nambi P, Pullen M, Wu HL, Lee D, Saunders D, Heys R, Aiyar N, Leber J, Elliott J, Brooks D, Ohlstein E, Ruffolo R.J Pharmacol Exp Ther. 1996 Jun;277(3):1567-71. PMID: 8667224 10:Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Ruetten H, Thiemermann C, Vane JR.Br J Pharmacol. 1996 May;118(1):198-204. PMID: 8733596 Free PMC Article